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Abstract
IMPORTANCE Individually, higher bodymass index (BMI) and alcohol consumption increase the risk
of liver disease. Evidence of a joint association is mixed; however, previous studies have not used
causal inferencemethods robust to confounding and reverse causation. Understanding any true
effect is key to developing effective interventions to reduce liver disease.
OBJECTIVE To investigate the joint association of BMI and alcohol consumption with liver injury
biomarkers and incident liver disease using factorial mendelian randomization (MR).
DESIGN, SETTING, ANDPARTICIPANTS A population-based cohort study (Copenhagen General
Population Study) recruited a random sample of Copenhagen, Denmark, residents aged 20 years or
older of white, Danish descent (N = 98643) between November 25, 2003, and July 1, 2014. Data
were also obtained from ongoing links to national registers, and then analyzed from September 30,
2016, to April 23, 2018.
EXPOSURES High and lowBMI and alcohol consumption categories frombaseline-measured or self-
reported observational data and genetic variants predicting BMI and alcohol consumption.
MAINOUTCOMESANDMEASURES Plasma biomarkers of liver injury (alanine aminotransferase
[ALT] and γ-glutamyltransferase [GGT]) and incident cases of liver disease from hospital records
were the outcomes.
RESULTS Of the 98643 individuals recruited, 91 552 (54 299 [45.2%] women; mean [SD] age, 58
[13.05] years) with no baseline liver disease were included in main analyses. Individuals had a mean
(SD) BMI of 26.2 (4.3) and consumed amean (SD) of 10.6 (10.2) U/wk of alcohol. In factorial MR
analyses, considering the high BMI/high alcohol group as the reference, mean circulating ALT and
GGT levels were lowest in the low BMI/low alcohol group (ALT: −2.32%; 95% CI, −4.29% to −0.35%,
and GGT: −3.56%; 95% CI, −5.88% to −1.24%). Individuals with low BMI/high alcohol use and high
BMI/low alcohol use also had lower mean circulating ALT levels (low BMI/high alcohol use: −1.31%;
95% CI, −1.88% to −0.73%, and high BMI/low alcohol use: −0.81%; 95% CI, −2.86% to 1.22%) and
GGT levels (low BMI/high alcohol use: −0.91%; 95% CI, −1.60% to −0.22%, and high BMI/low alcohol
use: −1.13%; 95% CI, −3.55% to 1.30%) compared with the high BMI/high alcohol use reference
group. These patterns were similar in multivariable factorial analyses. For incident liver disease
(N = 580), factorial MR results were less conclusive (odds ratio of liver disease vs high BMI/high
alcohol group: 1.01; 95% CI, 0.84 to 1.18, for the low BMI/high alcohol group, 1.22; 95% CI, 0.56 to
1.88 for the high BMI/low alcohol group, and 0.99 (95% CI, 0.41 to 1.56 for the low BMI/low
alcohol group).
(continued)
Key Points
Question Is there a joint association of
body mass index and alcohol
consumption with liver disease and liver
injury biomarkers?
Findings In this mendelian
randomization study of a population-
based cohort of 91 552 European adults,
compared with individuals categorized
as having both a high body mass index
and weekly units of alcohol
consumption, those in the low category
for both of these risk factors were
associated with lower circulating liver
injury biomarkers compared with being
high for either one or both of the risk
factors. However, this association was
less clear when considering cases of liver
disease as the outcome.
Meaning Interventions to reduce both
body mass index and alcohol
consumptionmay result in the greatest
reduction in circulating liver injury
biomarkers, but these results do not
appear to be able to demonstrate
whether these interventions will result
in a reduction in cases of liver disease.
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(3):e190305. doi:10.1001/jamanetworkopen.2019.0305 (Reprinted) March 8, 2019 1/14
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 03/27/2019
Abstract (continued)
CONCLUSIONS ANDRELEVANCE Interventions to reduce both BMI and alcohol consumption
might reduce population levels of biomarkers of liver injury more than interventions aimed at either
BMI or alcohol use alone. However, it is not clear whether this intervention will directly translate to a
reduced risk of liver disease.
JAMA Network Open. 2019;2(3):e190305. doi:10.1001/jamanetworkopen.2019.0305
Introduction
The risk of liver disease has increased, and the age at first diagnosis has decreased in many high-
income countries in recent decades.1 A key contributor is likely to be the global obesity epidemic and
the association between greater adiposity and nonalcoholic fatty liver disease.2 Increasing or
sustained unhealthy levels of alcohol consumption in some countries are also likely to have
contributed to the increase.3
Laboratory-based studies have suggested that shared biochemical pathways exist between
adiposity and alcohol leading to liver disease, including via insulin resistant pathways.4 Epidemiologic
studies suggest that overweight and alcohol consumption positively interact on amultiplicative scale
to increase the risk of pathologic liver changes, suggesting the relative risk of liver disease in people
who drink excessively and are overweight or obese is greater than would be expected if the 2 risk
factors were independent.5 Consistent with these findings, several studies have found that greater
bodymass index (BMI) and alcohol consumption positively interact in association with biomarkers of
liver injury, such as alanine aminotransferase (ALT), aspartate aminotransferase, and
γ-glutamyltransferase (GGT).6,7 By contrast, in a study of British women (approximately 1.2 million
womenwith 1811 occurrences of a first hospital admission or death from liver cirrhosis), there was no
evidence of an interaction between BMI and alcohol associated with cirrhosis.8
Understanding the combined effects of BMI and alcohol consumption on liver disease is
important for developing preventive public health interventions and establishing the likely future
burden of liver disease in populations with differing levels of high BMI and high alcohol consumption.
Previous findings from observational studies might be explained by residual confounding,
misclassification bias, or reverse causality. Mendelian randomization (MR), the use of genetic variants
as instrumental variables for assessing the effect ofmodifiable exposures, is increasingly used to infer
causal relationships between risk factors and outcomes. Some of the key strengths of MR include
beingmore robust to reverse causality, confounding, andmeasurement error than traditional
observational multivariable epidemiologic studies.9,10 These biases are important when considering
an exposure such as alcohol consumption, which is typically poorly reported by individuals and is
influenced bymultiple socioeconomic, lifestyle, and health factors. Mendelian randomization can be
used in a factorial design when considering how 2 or more risk factors may work together to
influence an outcome, comparable to a factorial, randomized clinical trial design (Figure 1, adapted
from Ference et al12).
The aim of this study was to use observational regression and factorial MR analyses to
investigate the joint association of BMI and alcohol consumption with liver injury biomarkers (ALT
and GGT) and liver disease.
Methods
We used data from the Copenhagen General Population Study (N = 98643), a large population
cohort with genotypic and phenotypic data on a wide range of health-related problems.
Copenhagen, Denmark, residents 20 years or older and of white, Danish descent were randomly
recruited from the national Danish Civil Registration between November 25, 2003, and July 1, 2014.
Data were also obtained from ongoing links to national registers and then analyzed from September
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30, 2016, to April 23, 2018. Ethics approval for the study was obtained fromHerlev Hospital and the
Danish ethical committee, and all participants provided written informed consent. Participants did
not receive financial compensation. Additional study details have been published.13 This study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.
Genetic data were available on 96 185 participants (98%). Bodymass index and alcohol data
were missing for a further 387 individuals, leaving 95 798 participants (97%) available for analysis.
There were some further missing data for additional covariables (smoking, physical activity, income,
and educational level) in 2732 individuals, who were subsequently excluded from analyses. A
diagnosis of liver disease is likely to result in treatment and lifestyle changes; therefore, individuals
with known liver disease (as defined by International Classification of Diseases [ICD] codes listed in
eTable 1 in the Supplement and described below) at baseline (prevalent cases) were excluded from
ourmain analyses (Figure 2).
All measurements were completed by trained staff at 1 clinic center. Weight was measured
without shoes and in light clothing to the nearest 0.1 kg (Soehnle Professional scales). Height was
measured to the nearest 0.1 cm (seca stadiometer). Usual alcohol intake was reported as weekly
consumption of beer in bottles and standard glasses of wine and spirits. Each of these products in
Denmark contains 1 U of alcohol or the equivalent of approximately 12 g of pure alcohol.
We used 5 genetic variants that were available in the database and are associated with BMI and
fatmass to create aweighted allele score as an instrumental variable for BMI: FTO rs9939609, TMEM18
rs6548238, MC4R rs17782313, BDNF rs10767664, and GNPDA2 rs6548238. In the absence of
genome-wide data, these variants were chosen for genotyping because they have the largest known
common effect sizes for the association with BMI in European populations.14 This score was externally
weighted according to the β value for each genetic variant association with BMI from themost recent
genome-wide association study.14 A single genetic variant, ADH1B (rs1229984, Arg47His in exon 3),
was used as an instrumental variable for alcohol consumption. This variant is associated with alcohol
consumption, as demonstrated in previous analyses using these data.11,13 Genotyping was conducted
by laboratory technicians without access to participant data (ABI PRISM 7900HT Sequence Detection
System; Applied Biosystems Inc) and TaqMan assays. Genotyping was verified by DNA sequence in at
Figure 1. FlowDiagram for the Generation of Factorial Groups, Using Observational and Genetic Data
Measured/weighted allele for BMI
Below or equal to median
of measured BMI or
BMI-weighted allele score
Below or equal to median
of alcohol consumption
or ADH1B genotype
Low BMI and low alcohol
consumption
Above median of alcohol
consumption
or ADH1B genotype
Low BMI and high alcohol
consumption
Below or equal to median
of alcohol consumption
or ADH1B genotype
High BMI and low alcohol
consumption
Above median of alcohol
consumption
or ADH1B genotype
High BMI and high 
alcohol consumption
Dichotomize participants
by median of first variable
of interest
Dichotomize by the
second variable of interest
Above median of
measured BMI or
BMI-weighted allele score
Factorial multivariable: both bodymass index (BMI) and weekly alcohol consumption
were dichotomized based on themedian of measured or self-reported values. Values
equal to or below the median were categorized as the low group, and those above the
median were categorized as the high group. Factorial mendelian randomization (MR):
For genetic propensity, BMI was categorized according to the median of the weighted
allele score for BMI, with values equal to or below themedian categorized as low BMI and
those above themedian categorized as high BMI. Alcohol propensity was determined
according to ADH1B alleles. Individuals whowere homozygous for the alcohol-decreasing
traits and heterozygous individuals were combined, as determined to be appropriate
based on previous MR analyses of these traits on alcohol intake,11 to create the low
alcohol-propensity group. The high alcohol-propensity group contains all individuals
homozygous for the alcohol-increasing trait. Adapted from Ference et al.12
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least 30 individuals with each genotype. Reruns were performed twice and 99.96% of all available
participants were genotyped.
Nonfasting plasma ALT and GGT levels were measured at baseline using standard hospital
assays (Konelab, Thermo Fischer Scientific, Denmark, and ACL Top blood coagulation analyzer, ILS
Denmark) and were subject to daily internal quality control assessing assay precision and monthly
external quality control assessing assay accuracy. Participants were linked to their hospital records
providing information on all admissions and outpatient appointments before and after study
recruitment, with diagnosesmade according to routine clinical care. These hospital records identified
individuals with existing chronic liver disease and thosewho developed liver disease during follow-up
(incident cases). Participants were also linked to death records. The following ICD diagnostic terms,
incorporating both alcoholic and nonalcoholic modifiable causes, were included as cases of chronic
liver disease: cirrhosis, including alcoholic fatty liver; unspecified chronic liver disease without
mention of alcohol; hepatic fibrosis; malignant neoplasms of the liver; acute and subacute necrosis
of the liver; chronic passive congestion of the liver; unspecified disorder of the liver; abdominal
swelling; and other nonspecific liver disease.15 eTable 1 in the Supplement provides the ICD
codes used.
Participants completed a questionnaire that recorded details on smoking (never vs ever
smoker), physical activity (low, 0-4 hours per week vs high, >4 hours per week), income (low/middle
income,600.000kr [$66 348 US$] per year vs high income, >600.000kr per year), and
educational attainment (low/middle education,13 years of schooling vs high education >13 years),
which were included as covariables.
Figure 2. Missing Data and Total Number of Participants for Each Analysis
98 643 Participants in the Copenhagen General Population
Study; Danish adults aged ≥20 y
96 185 With genetic data (98%)
95 798 With genetic and risk factor data (97%)
2458 Missing genetic data
1873 Missing BMI
718 Missing alcohol consumption
387 Missing risk factor data
326 Missing BMI
62 Missing alcohol consumption
2732 Missing covariable data
585 Missing smoking
749 Missing physical activity
1185 Missing income
291 Missing educational level
811 Missing any outcomes
806 Missing ALT level
808 Missing GGT level
0 Missing liver disease
Included in multivariable and MR analyses
91 552 Incident cases only (703 prevalent cases removed)
(including 580 cases)
92 255 Incident and prevalent cases (including 1283 cases)
Participants could have hadmissing data for more than
1 variable at each stage; hence, the additive numbers
missing for each variable can total more than the
number removed at that stage. ALT indicates alanine
aminotransferase; BMI, body mass index; GGT,
γ-glutamyltransferase; MR, mendelian randomization.
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Statistical Analysis
We explored the separate and joint associations of BMI and alcohol consumption with ALT, GGT, and
liver disease using both observational multivariable andMR analyses. In multivariable andMR
analyses, the results reflect the samemagnitude of change in exposures (ie, 1-SD score higher BMI or
1-U greater alcohol intake on outcome). Alanine aminotransferase and GGT levels were natural
log-transformed to normalize the distribution of residuals in regressionmodels. Bodymass indexwas
standardized for age (5-year groups) and sex into SD scores. Both themultivariable analysis andMR
analysis are on a multiplicative scale, and results for biomarkers are presented as percentage
differences inmean levels per 1 BMI SD or 1 U of alcohol. All analyses were conducted in Stata, version
15 (StataCorp).
Multivariable Analyses
In multivariable analyses, we examined BMI in categories of normal weight or underweight (<25.0
[calculated asweight in kilograms divided by height inmeters squared]), overweight (25.0-29.9), and
obese (30.0), and as a continuous BMI SD score. We examined alcohol use in categories of none, 1
to 14, and 15 U or more per week, and per unit of alcohol consumption per week. We used
multivariable linear regression to examine associations with ALT and GGT levels and logistic
regression for associations with liver disease.
To examine joint associations of BMI and alcohol consumption with markers of liver injury, a
factorial analysis was completed by categorizing participants in 4 groups according to their measured
values of the exposure: high BMI/high alcohol consumption (reference), high BMI/low alcohol
consumption, high alcohol consumption/low BMI, and low BMI/low alcohol consumption. Low and
high BMI were defined as less than or equal to or greater than median BMI SD score, respectively.
Similarly, low and high alcohol consumption were defined as less than or equal to or greater
than median alcohol consumption, respectively. Themean difference between the high and low
groupswas 1.49 per SD of BMI and 14.68U/wk for alcohol consumption (Figure 1). Multivariable linear
or logistic regressionwas then used to assess the association of each of these groupswith outcomes.
Stratified analyses of BMI SD score with each outcome by strata of alcohol consumption (none, <15,
and15 U/wk) were also performed. A likelihood ratio test was used to test for statistical evidence of
interaction by comparing a model with BMI SD score and alcohol categories independent with one
where an interaction termwas included.
For all multivariable analyses, we considered the best estimate of an effect to be adjusted for all
observed variables that we considered potential confounders (age, sex, cigarette smoking, physical
activity, educational attainment, and income) and individuals with baseline liver disease removed.
MRAnalyses
An exact test was used to examine Hardy-Weinberg equilibrium of genotype frequencies.16 We
present the first-stage (regression of risk factor on genetic instrument) F statistic and R2 as ameasure
of the association between genetic instruments and observed phenotype.Wemeasured associations
of BMI and alcohol consumption instruments with observed confounders to test our a priori
assumption of no confounding associations. Mendelian randomization analyses were completed
using the 2-stage least squares instrumental variable regression method for continuous outcomes.
For the binary outcome (liver disease), MRwas run in 2 regression stages, including robust SEs in the
second stage.17,18
As with multivariable analyses, a factorial analysis was completed to test joint associations,
categorizing participants to the same 4 groups previously described according to genetic
propensities. Low and high BMI were defined as less than or equal to or greater thanmedian
BMI-weighted allele score, respectively. Alcohol consumption was dichotomized according to ADH1B
alleles, where individuals homozygous for the alcohol-decreasing allele or heterozygous for ADH1B
were classed as low alcohol consumption, and the high alcohol consumption group comprised
individuals homozygous for the alcohol-increasing allele of ADH1B11 (Figure 1). Themean difference
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between the high and low groups was 0.51 BMI SD and 1.78 U/wk for alcohol consumption (Figure 1).
Regressionmethods were then used to assess the association of each of these groups with
outcomes. We investigated evidence of an interaction between BMI and alcohol consumption using
stratified MR of the BMI-weighted allele score instrument by self-reported weekly alcohol
consumption (none, <15, and15 U/wk). A variance-weighted, least squares approach was used to
test for statistical evidence of a difference in circulating biomarkers and liver disease risk across
alcohol strata. This evaluation was done by calculating a χ2 test to assess for deviations between
point estimates in each stratum.
ComparingMultivariable andMRResults
We compared themultivariable andMR results by using a χ2 test to examine the null hypothesis that
the coefficients are consistent with one another. Wemade this comparison for analyses of the
association of BMI and alcohol separately, and for the stratified results of the association of 1-SD
greater BMI within the strata of reported alcohol consumption. Wewere not able to compare the
magnitude of effect sizes of themultivariable andMR factorial analyses because it was not possible
to split participants into high and low BMI and alcohol groups in identical ways for the 2 methods.
Thus, in themultivariable analyses, the high vs low results reflect a 1.49-SD difference in BMI and a
14.68-U difference in units of weekly alcohol consumption, whereas the equivalent differences in the
MR analyses are 0.51 SD and 1.78 U/wk, respectively. We did, however, compare the directions and
overall patterns of association for the factorial results.
Sensitivity Analyses
Sensitivity analyses were completed to test the robustness of our MR results for the associations of
BMI on outcomes. These analyses included using methods that are more robust to pleiotropic
variants (ie, weightedmedianmethods andMR-Egger method),19,20 and assessing the association of
outlying variants by removing 1 variant at a time and recalculating the overall MR estimate (ie, leave-
1-out analysis). Because we have only 1 genetic variant for alcohol, these sensitivity analyses were not
possible. For MR analyses of both BMI and alcohol consumption, we adjusted for income and
smoking because of some evidence of genetic instrument associations with these variables as a
sensitivity analysis. All analyses were repeated with individuals with prevalent cases of liver disease
included.
Results
Of the 98643 participants, 91 552 (54 299 [45.2%]women;mean [SD] age, 58 [13.05] years) with no
baseline liver diseasewere included inmain analyses. A total of 9.4%of the participants reported not
drinking alcohol and 12.3% reported drinking 22 U/wk or more (eTable 2 in the Supplement). Both
alcohol intake and BMI differed by sex (eTable 2 in the Supplement). In women, 12.4% reported not
drinking alcohol compared with 5.8% of men. Conversely only 0.8% of women reported drinking
more than 22 U per week, compared with 5.8% of men. A total of 42.9% of the participants were
normal weight; 0.7%, underweight; 40.2%, overweight; and 16.3%, obese. There was a greater
proportion of womenwhowere normal weight (52.3%) compared with men (32.7%), and a greater
proportion of overweight men (49.7%) compared with women (32.4%) (eTable 2 in the
Supplement). The sex distribution was equal in the high or low genetic factorial groups, as would be
expected given the assumption of no confounding in MR, but differences were present in the
observational factorial groups (eTable 3 in the Supplement).
There were 1405 cases (1.4%) of either prevalent or incident liver disease, with 616 (0.6%)
incident cases. Of these cases, there were 420 prevalent cases of alcohol-induced liver disease and
356 incident cases of alcohol-induced liver disease (eTable 2 in the Supplement). All measured
confounders were associated with reported alcohol intake andmeasured BMI (eTable 4 in the
Supplement). For example, compared with never smokers, current or former smokers had an
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increased BMI of 0.36 (95%CI, 0.30-0.41) and an increased alcohol consumption of 2.90U/wk (95%
CI, 2.77-3.03 U/wk), but most were not associated with ADH1B or the BMI-weighted allele score
(eTable 5 in the Supplement). There was some evidence that the BMI-weighted allele score was
positively associated with smoking and negatively associated with income, where the BMI-weighted
allele score was increased by 0.002 U (95% CI, 0.0006-0.003 U) for current or former smokers
compared with never smokers,. All observed confounders were associated with the factorial groups
in multivariable analysis; none were associated with factorial groups in MR analysis (eTable 6 in the
Supplement). The minor allele frequencies for all 5 genotypes are reported in eTable 7 in the
Supplement; all were in Hardy-Weinberg equilibrium. The first-stage partial F statistic and R2 for the
combined weighted allele score for BMI were 453 and 0.0049, and for ADH1B were 117 and 0.0013,
respectively (eTable 8 in the Supplement).
In bothmultivariable andMR analyses, individually higher BMI and higher alcohol consumption
were associated with higher mean ALT and GGT levels and odds of incident liver disease (Figure 3).
Overall, multivariable and MR results were consistent with each other, although point estimates for
ALT and GGT levels appeared slightly larger in multivariable compared with MR analyses (Figure 3A
and B). For both methods, the associations with ALT and GGT levels were similar for BMI, whereas
the association of alcohol consumption with GGT was more than double the magnitude of the
association of alcohol with ALT levels, although in both cases the associations are small and the 95%
CIs overlap.
Larger associations of both BMI and alcohol consumption were seen in theMR analysis
compared with multivariable regression for incident liver disease. However, the 95% CIs in the MR
analyses were wide and included the null value, particularly in the case of BMI (Figure 3C). Analysis
including individuals with prevalent cases of liver disease showed similar estimates of associations
with analyses restricted to incident cases (eFigure 1 and eFigure 2 in the Supplement).
Multivariable analysis indicated a linear association of increasing BMI and increasing alcohol
consumption with increasing levels of biomarkers for liver injury and odds of disease (eFigure 3 and
eFigure 4 in the Supplement); nonlinear associations were not tested in MR analyses.
In bothmultivariable andMR factorial analyses, patients in the low BMI/low alcohol
consumption groups had the lowest mean ALT and GGT levels in comparison with those in the
highest categories of both biomarkers. In factorial MR analyses, mean circulating ALT and GGTwere
reduced by −2.32% (95% CI, −4.29% to −0.35%) and −3.56% (95% CI, −5.88% to −1.24%),
respectively. Individuals with low BMI/high alcohol use and high BMI/low alcohol use also had lower
mean circulating ALT levels (low BMI/high alcohol use: −1.31%; 95% CI, −1.88% to −0.73% and high
BMI/low alcohol use: −0.81%; 95% CI, −2.86% to 1.22%, respectively) and GGT levels (low BMI/high
alcohol use: −0.91%; 95% CI, −1.60% to −0.22% and high BMI/low alcohol use: and −1.13%; 95% CI,
−3.55% to 1.30%) compared with the high BMI/high alcohol use reference group. These patterns
were similar in multivariable factorial analyses (Figure 4A-D). In both sets of analyses, being in the
low BMI/high alcohol consumption group conferred a greater protective association with ALT levels
than those in the high BMI/low alcohol consumption group compared with the reference group.
However, for GGT levels, being low for either BMI or alcohol consumption had almost identical
protective associations compared with the reference group, in bothmultivariable andMR analyses.
These results for liver biomarkers were similar when individuals with prevalent cases of liver disease
were included in the analysis (eFigure 5 in the Supplement).
For the odds of incident liver disease, factorial multivariable regression analyses had a pattern
similar to that of the biomarkers (ie, reduced odds in those with both low BMI and alcohol intake, in
comparisonwith those high for both risk factors, and in between for the 2mixed groups) (Figure 4E
and F). This pattern was not consistent in the factorial MR analyses. These patterns were similar in
multivariable factorial analyses. For incident liver disease (N = 580), factorial MR results were less
conclusive (odds ratio of liver disease vs high BMI/high alcohol group: 1.01; 95% CI, 0.84 to 1.18, for
the low BMI/high alcohol group, 1.22; 95% CI, 0.56 to 1.88 for the high BMI/low alcohol group, and
0.99 (95% CI, 0.41 to 1.56 for the low BMI/low alcohol group). When analyses were repeated with
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both incident and prevalent liver disease included as the outcome, factorial multivariable analyses
suggested that patients with low BMI/high alcohol intake had reduced odds similar to those with low
values of both risk factors, which was not confirmed by factorial MR (eFigure 6 in the Supplement).
In stratified multivariable analyses, the positive association of BMI with all outcomes was
strongest in patients consuming 15 U or more of alcohol per week compared with those not drinking
alcohol or drinking less than 15 U per week. There was statistical support for a positive interaction
on amultiplicative scale between the 2 risk factors for ALT and GGT levels; this evidence was weaker
for the odds of liver disease, but the pattern of interactionwas similar (eFigure 7 in the Supplement).
The same pattern of positive multiplicative interaction of BMI and alcohol consumption was not
observed for any of the outcomes in MR analyses (eFigure 7 in the Supplement). For ALT and GGT
levels, the MR results suggested a weaker positive association of BMI in those with highest alcohol
consumption (15 U/wk), although these associations were imprecisely estimated, and we found no
Figure 3. Multivariable andMendelian Randomization Analyses of the Individual Associations of BodyMass Index (BMI) and Alcohol Consumption
With Liver Enzyme Levels AssociatedWith Injury and Incident Liver Disease
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weighted allele score for BMI andADH1B alleles for alcohol consumption. Prevalent cases
of liver disease were excluded from all analyses.
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strong evidence for any interaction. For liver disease, the stratified MR analyses were particularly
imprecise, although again results suggested, if anything, a negative interaction.
Sensitivity Analyses
WeightedmedianMR andMR-Egger estimates for the association of BMI with outcomes were
broadly similar to our main MR analyses results (eTable 9 in the Supplement). Heterogeneity
between the 5 BMI-related genetic variants used as instrumental variables in MRwasmodest
(I2 = 52% for ALT level, 13% for GGT level, and 38% for the odds of incident liver disease). Results
were consistent when 1 genetic variant at a timewas removed, although for both ALT and GGT levels,
the estimates were attenuated slightly when FTO was removed (eFigure 8 in the Supplement).
Adjustment of the MR analyses for smoking and income did not notably influence the results.
Figure 4. Multivariable andMendelian Randomization (MR) Factorial Analyses Assessing the Joint Associations of BodyMass Index (BMI) and Alcohol
With Biomarkers of Liver Injury and Incident Liver Disease
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A, Multivariable regression of percentage difference in mean alanine aminotransferase
(ALT) level by joint observational BMI and alcohol categories. B, MR of percentage
difference in mean ALT level by joint genetic BMI and alcohol categories. C, Multivariable
regression of percentage difference in mean γ-glutamyltransferase (GGT) level by joint
observational BMI and alcohol categories. D, MR of percentage difference in mean GGT
level by joint genetic BMI and alcohol categories. E, Multivariable regression of odds
ratio (OR) of liver disease by joint observational BMI and alcohol categories. F, MR of OR
of liver disease by joint genetic BMI and alcohol categories. Low vs high BMI (calculated
as weight in kilograms divided by height in meters squared), 1.49-SD difference in
multivariable analyses and 0.51 SD in MR analyses. Low vs high alcohol, 14.68 U/wk
difference in multivariable analyses and 1.78 U/wk difference in MR analyses, where 1 U
of alcohol is equivalent to 12 g. Multivariable analysis was adjusted for age, sex, smoking,
educational level, income, and physical activity.
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Discussion
Using bothmultivariable andMR analyses, we have shown that higher BMI and alcohol consumption
are associated with higher circulating levels of ALT and GGT individually and jointly andmay infer a
causal relationship. The broad consistency of findings between multivariable and MR analyses for
each exposure individually, and both jointly, on ALT and GGT provides more compelling evidence for
potential causality than either method alone as they each have different key sources of bias.21
Mendelian randomization findings for incident liver disease suggested larger estimates of an
association with both BMI and alcohol intake than the observational multivariable findings in
multivariable analyses or horizontal pleiotropy exaggerating associations in MR analyses. However,
these estimates were imprecise and the wide 95% CIs for BMI included the null value.
Consistent with individual associations, multivariable andMR factorial analyses suggested that
adults with low BMI/low alcohol consumption had lower ALT and GGT levels compared with those
with high levels of both risk factors. Patients with low levels of 1 risk factor had intermediate levels of
ALT and GGT. The higher concentrations of ALT and GGT in the high BMI/high alcohol intake group
could reflect the combination of independent associations of BMI and alcohol intake or a positive
interaction between the 2 risk factors. We found some evidence of positive multiplicative
interactions of BMI and alcohol intake with ALT and GGT levels in multivariable analyses, but not in
MR analyses. For incident liver disease, themultivariable factorial and stratified analyses followed the
same pattern of those seen with ALT and GGT levels, whereas in MR analyses there was no clear
evidence of differences across factorial groups. However, 95%CIs for factorial or interaction analyses
for incident liver disease were wide, suggesting a lack of statistical power despite the large
sample size.
Our multivariable analyses are consistent with most previously published studies of the
individual associations of BMI and alcohol intake on liver biomarkers and disease.5,11,15 Using MR in a
smaller number of participants from the same study population as used here (N = 58 313), a possible
causal association of greater alcohol consumption on ALT and GGT levels was shown.11 We have
added to that previous work by estimating the associations of increasing BMI with ALT and GGT
levels as well as an incident liver disease and undertaking the first, to our knowledge, MR analyses of
the joint associations of BMI and alcohol intake with these outcomes. Consistent with our
multivariable analyses, some,6,7 although not all,8 previous multivariable studies reported a positive
multiplicative interaction between higher BMI and alcohol consumption with liver biomarkers and
disease. However, our MR analyses suggest that BMI and alcohol intake combine as we would expect
if their individual associations with ALT and GGT levels are independent of each other, as we
observed a nonlinear pattern in stratified MR, and possibly with smaller associations than
independence for liver disease, although power would have been low. In the absence of other MR
studies of these joint associations, we suggest caution regarding the joint associations with liver
disease outcomes.
Strengths and Limitations
Our study has several strengths, including the large sample size, the assessment of potential single
and joint associations of BMI and alcohol intake with liver biomarker and disease outcomes using
bothmultivariable andMR, and appropriate sensitivity analyses to test the robustness of the MR
assumptions. To our knowledge, because they are relatively rare, incident cases of liver disease have
not been explored previously withMR or inmanymultivariable regression studies. The study of liver
biomarkers, high levels of which reflect cell damage in the liver and biliary track, as well as disease
outcomes, is valuable for indicating propensity to future disease and allowing analyses with greater
statistical power.
The study also has limitations. Mendelian randomization andmultivariable analyses are
potentially biased by violation of their assumptions. Multivariable approaches assume that all
confounders have been accurately measured and accounted for, and that there is no reverse
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causation, selection bias, or systematic measurement error that distorts the estimate.21 The removal
of patients with prevalent liver disease in our main analyses should have limited potential survivor
bias and reverse causality. We adjusted for key observed potential confounders, but residual
confounding by unmeasured confounders or imprecise measurement might bias estimates in our
multivariable analyses. For the individual associations of BMI and alcohol usewith ALT and GGT levels
as well as liver disease, multivariable results were similar to the MR results, which are less prone to
confounding, suggesting that residual confoundingmight not be amajor issue.22 However, the larger
individual associations in MR analyses of liver disease might mean that multivariable results were
biased bymasking residual confounding.
Mendelian randomization analyses assume that there is a robust association between the
genetic instrument and risk factor, that the genetic instrument is not associated with confounders of
the risk factor–outcome association, and that there is no influence of the genetic instrument on the
outcome other than via the risk factor of interest (the latter may be violated by horizontal
pleiotropy).9,23,24 We found some association of BMI genetic variants with smoking and income, but
adjustment for these variables in the MR analyses did not alter results. The Copenhagen General
Population Study participants are ethnically and geographically homogeneous, which reduces the
risk of confounding due to population stratification. However, this homogeneity means that results
may not generalize to other ethnic groups. Our sensitivity analyses suggest some greater influence of
one of the BMI genetic variants (FTO) than other variants, but the results were notmarkedly different
and our conclusions were not altered by its removal.
Another limitation of both analyses is that individuals reporting no consumption of alcohol may
be a heterogeneous group of life-long abstainers and those who have previously consumed alcohol
but have since become abstainers. However, the multivariable regression results suggest linear
associations of increasing consumption from this group of nondrinkers and the similarity of analyses
including and excluding prevalent disease cases suggest that this combination of abstainers is
unlikely to have introducedmajor bias.
There is potential for somemisclassification of liver disease cases as controls because not all
cases (particularly those in the early stages) result in hospital admission or outpatient visits, and
primary care records are not included in the routinely linked data used here. This lack of data would
result in a diluted estimate of the association of BMI and alcohol consumption with liver disease.
However, it would be expected that these patients would have elevated levels of ALT and GGT
compared with individuals with no liver disease. This potential for misclassification of disease status
provides a possible explanation for the differences observedwhen estimating the association of BMI
and alcohol use with liver disease, compared with the continuous measurement of liver injury
biomarkers.
Conclusions
Taking account of both our multivariable andMR results, this study suggests that the associations
between high BMI and alcohol consumption with liver injury and risk of liver disease may act
independently and that these risk factors may increase biomarkers of liver injury and risk of liver
disease. Interventions to reduce both of these risk factors might produce the greater benefit in terms
of reducing population levels of biomarkers of liver injury than interventions aimed at either BMI or
alcohol use alone. However, the current evidence is not clear whether reducing both BMI and alcohol
consumption in combination will directly translate to a reduced risk in clinical liver disease; further
studies are required to identify the true joint causal effect of BMI and alcohol use on liver disease.
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